CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: IFNAR1 (ImmuneEditome ID:3454)

1. Gene summary of enriched editing regions for IFNAR1

check button Gene summary
Gene informationGene symbol

IFNAR1

Gene ID

3454

GeneSynonymsAVP|IFN-alpha-REC|IFNAR|IFNBR|IFRC|IMD106
GeneCytomap

21q22.11

GeneTypeprotein-coding
GeneDescriptioninterferon alpha/beta receptor 1|CRF2-1|IFN-R-1|IFN-alpha/beta receptor 1|IFNalpha/beta receptor 1|alpha-type antiviral protein|beta-type antiviral protein|cytokine receptor class-II member 1|cytokine receptor family 2 member 1|interferon (alpha, beta and omega) receptor 1|interferon receptor 1|interferon-alpha/beta receptor alpha chain|interferon-beta receptor 1|type I interferon receptor 1
GeneModificationdate20230518
UniprotIDP17181;A0A494C0P2;A0A494C0E2;A0A494C0K3;A0A494BZU5
PubMed ID

35833131

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr21:33355740-33355909:+ENST00000270139.6ENSG00000142166.11IFNAR1UTR3AluScchr21:33355740-33355909:+.alignment
chr21:33357576-33358815:+ENST00000270139.6ENSG00000142166.11IFNAR1UTR3AluJr,AluSg7,(AATATAT)nchr21:33357576-33358815:+.alignment


Top

2. Tumor-specific enriched editing regions for IFNAR1


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr21:33357576-33358815:+BRCAEER3.6532e-27image
ENSG00000142166.11,IFNAR1BRCAEAG3.1348e-17image
chr21:33357576-33358815:+COADEER5.1563e-10image
ENSG00000142166.11,IFNAR1COADEAG3.2930e-08image
chr21:33357576-33358815:+HNSCEER9.6546e-06image
ENSG00000142166.11,IFNAR1HNSCEAG1.9334e-05image
chr21:33357576-33358815:+KIRCEER1.0742e-07image
ENSG00000142166.11,IFNAR1KIRCEAG2.6319e-06image
chr21:33357576-33358815:+KIRPEER3.8146e-03image
ENSG00000142166.11,IFNAR1KIRPEAG9.4160e-03image
chr21:33357576-33358815:+LIHCEER2.2922e-02image
ENSG00000142166.11,IFNAR1LIHCEAG9.9579e-03image
chr21:33357576-33358815:+LUADEER3.4259e-07image
ENSG00000142166.11,IFNAR1LUADEAG5.4092e-08image
chr21:33357576-33358815:+LUSCEER3.8171e-05image
ENSG00000142166.11,IFNAR1LUSCEAG2.3686e-05image
chr21:33357576-33358815:+STADEER7.5763e-03image
ENSG00000142166.11,IFNAR1STADEAG1.4305e-02image
ENSG00000142166.11,IFNAR1THCAEAG7.6842e-07image
chr21:33357576-33358815:+UCECEER4.3065e-04image
ENSG00000142166.11,IFNAR1UCECEAG1.7614e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr21:33357576-33358815:+BRCAPathEER1.7584e-052.3319e-030.0936image
ENSG00000142166.11,IFNAR1BRCAPathEAG1.8562e-051.4233e-030.0981image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
ENSG00000142166.11,IFNAR1COADEAG3.9131e-021.1567e-022.6830e+01image
chr21:33357576-33358815:+LGGEER9.9695e-031.4944e-046.3262e+02image
ENSG00000142166.11,IFNAR1LGGEAG4.2983e-045.6703e-051.1912e+03image
chr21:33357576-33358815:+PAADEER4.6265e-023.0630e-027.8825e+01image
ENSG00000142166.11,IFNAR1PAADEAG9.5739e-031.3799e-021.2675e+02image
chr21:33357576-33358815:+SARCEER2.0498e-023.1487e-021.8162e+01image

Top

3. Enriched editing regions and immune related genes for IFNAR1


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr21:33357576-33358815:+LGGEERENSG00000138496,PARP90.44828.4612e-231.0108e-250.4352imageNRBFOX2;TAF15;DKC1;FAM120A;FBL;HNRNPK;PTBP1NAMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr21:33357576-33358815:+LGGEERENSG00000105612,DNASE20.44573.0488e-221.2155e-220.4091imageNRBFOX2;TAF15;FAM120A;FBL;HNRNPK;NUMA1;PTBP1DNASE2Macrophages_M2GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr21:33357576-33358815:+LGGEERENSG00000117280,RAB290.43948.5204e-225.0766e-250.4295imageNRBFOX2;TAF15;DKC1;FAM120A;FBL;HNRNPK;NUMA1;PTBP1NAMacrophages_M2GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr21:33357576-33358815:+LGGEERENSG00000204592,HLA-E0.43532.8842e-211.2525e-230.4177imageNRBFOX2;TAF15;FAM120A;FBL;HNRNPK;NUMA1;PTBP1HLA-ET_cells_CD4_naiveGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr21:33357576-33358815:+LGGEERENSG00000197324,LRP100.42826.6474e-211.2354e-210.4000imageNRBFOX2;TAF15;DKC1;FAM120A;FBL;HNRNPK;NUMA1;PTBP1LRP10NK_cells_activatedGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr21:33357576-33358815:+LGGEERENSG00000198105,ZNF248-0.41892.2020e-206.1906e-23-0.4117imageNRBFOX2;TAF15;DKC1;FAM120A;FBL;HNRNPK;NUMA1;PTBP1NAMacrophages_M1GSVA_HALLMARK_COAGULATION
chr21:33357576-33358815:+LGGEERENSG00000068724,TTC7A0.42105.2714e-201.1029e-220.4095imageNRBFOX2;TAF15;DKC1;FAM120A;FBL;HNRNPK;NUMA1;PTBP1NAT_cells_CD4_naiveGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr21:33357576-33358815:+LGGEERENSG00000059378,PARP120.42155.9685e-204.7480e-220.4038imageNRBFOX2;TAF15;DKC1;FAM120A;FBL;HNRNPK;PTBP1NAMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr21:33357576-33358815:+LGGEERENSG00000067066,SP1000.41781.1030e-195.9484e-230.4118imageNRBFOX2;TAF15;DKC1;FAM120A;FBL;HNRNPK;PTBP1SP100Macrophages_M1GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr21:33357576-33358815:+LGGEERENSG00000137628,DDX600.41761.4676e-197.5101e-230.4110imageNRBFOX2;TAF15;DKC1;FBL;PTBP1NAMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE

More results



Top

4. Enriched editing regions and immune related splicing for IFNAR1


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000142166.11,IFNAR1
CESCEAGMEXENSG00000070718.7chr842152945:42153105:42154477:42154536:42154565:42154960:42157940:421580850.24096.2585e-041.5916e-100.4185imageNAIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184NAB_cells_naiveGSVA_HALLMARK_MITOTIC_SPINDLE
chr21:33357576-33358815:+
CESCEERMEXENSG00000070718.7chr842152945:42153105:42154477:42154536:42154565:42154960:42157940:421580850.23897.9514e-042.3764e-100.4148imageNRBFOX2;TAF15;DKC1;FAM120A;FBL;HNRNPK;NUMA1;PTBP1NAB_cells_naiveGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000142166.11,IFNAR1
COADEAGA3ENSG00000165494.6chr1183177084:83177204:83177716:83177819:83177713:831778190.22282.3709e-021.6985e-140.4520imageNAIFM1;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_GLYCOLYSIS
chr21:33357576-33358815:+
GBMEERIRENSG00000171962.13chr1718015726:18016195:18016557:18016651-0.33191.3505e-032.2688e-08-0.4695imageNRBFOX2;TAF15;DKC1;FBLNAMacrophages_M0GSVA_HALLMARK_BILE_ACID_METABOLISM
chr21:33357576-33358815:+
GBMEERESENSG00000197535.10chr1552336462:52336556:52337809:52337884:52340195:523403940.30942.3043e-033.7303e-070.4476imageNRBFOX2;TAF15;DKC1;FAM120A;FBL;HNRNPK;NUMA1;PTBP1NAMonocytesGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000142166.11,IFNAR1
GBMEAGESENSG00000134121.5chr3341911:342082:342983:343031:344588:3447090.27371.4602e-035.1931e-060.4025imageNADAR;CELF2;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FBL;FUS;HNRNPA2B1;HNRNPC;HNRNPL;IGF2BP2;MBNL2;NOP56;NOP58;PTBP1;RBFOX2;RBM10;RBM5;SRSF10;SRSF3;TAF15;TARBP2;TARDBP;TROVE2;U2AF2;UPF1;ZNF184CHL1T_cells_gamma_deltaGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr21:33357576-33358815:+
GBMEERIRENSG00000162063.8chr162453209:2453537:2455394:24555640.31254.3612e-031.1895e-070.4506imageNRBFOX2;TAF15;DKC1;FAM120A;FBL;HNRNPK;NUMA1;PTBP1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V1
chr21:33357576-33358815:+
GBMEERESENSG00000102710.15chr1337009616:37009809:37010551:37010655:37012191:37012297-0.37361.4098e-039.9319e-08-0.4026imageNRBFOX2;TAF15;DKC1;FAM120A;FBL;HNRNPK;NUMA1;PTBP1NAMonocytesGSVA_HALLMARK_BILE_ACID_METABOLISM
ENSG00000142166.11,IFNAR1
GBMEAGIRENSG00000171962.13chr1718015726:18016195:18016557:18016651-0.34897.1005e-041.5760e-09-0.5020imageNADAR;DGCR8;DKC1;EIF4A3;ELAVL1;EWSR1;FBL;FMR1;FUS;GNL3;HNRNPA1;HNRNPC;HNRNPL;IGF2BP1;IGF2BP2;KHDRBS1;LIN28;LIN28B;NOP56;NOP58;RANGAP1;RBFOX2;RBM10;RNF219;SMNDC1;SND1;SRSF1;TAF15;TARDBP;TROVE2;U2AF1;U2AF2;UPF1;YTHDF1;ZNF184NAMacrophages_M0GSVA_HALLMARK_BILE_ACID_METABOLISM
ENSG00000142166.11,IFNAR1
GBMEAGESENSG00000088367.16chr2036197879:36198041:36209487:36209898:36212271:36212376-0.37201.5065e-034.9744e-08-0.4171imageNADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;RBM5;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;YTHDF2;YWHAG;ZNF184NAMonocytesGSVA_HALLMARK_BILE_ACID_METABOLISM

More results



Top

5. Enriched editing regions and immune infiltration for IFNAR1


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000142166.11,IFNAR1ACCEAGDendritic_cells_activated4.4683e-03-0.3407image
chr21:33357576-33358815:+BLCAEERT_cells_regulatory_(Tregs)1.3363e-04-0.2011image
ENSG00000142166.11,IFNAR1BLCAEAGT_cells_regulatory_(Tregs)6.4910e-05-0.2095image
chr21:33357576-33358815:+BRCAEERB_cells_naive8.1401e-04-0.1028image
ENSG00000142166.11,IFNAR1BRCAEAGB_cells_naive3.8940e-03-0.0886image
chr21:33357576-33358815:+CESCEERT_cells_CD4_memory_resting3.3569e-03-0.1741image
ENSG00000142166.11,IFNAR1CESCEAGT_cells_CD4_memory_resting5.1936e-03-0.1660image
chr21:33357576-33358815:+CHOLEERMacrophages_M21.4635e-02-0.4212image
ENSG00000142166.11,IFNAR1CHOLEAGMast_cells_resting7.7326e-03-0.4555image
chr21:33357576-33358815:+COADEERMacrophages_M12.2788e-030.1884image
ENSG00000142166.11,IFNAR1COADEAGDendritic_cells_activated1.2377e-020.1543image
ENSG00000142166.11,IFNAR1DLBCEAGNeutrophils2.1065e-020.3592image
chr21:33357576-33358815:+ESCAEERT_cells_follicular_helper2.5900e-02-0.1772image
ENSG00000142166.11,IFNAR1ESCAEAGNK_cells_resting5.9065e-030.2174image
chr21:33355740-33355909:+GBMEERDendritic_cells_resting4.0599e-020.3065image
chr21:33357576-33358815:+GBMEERMacrophages_M01.8931e-03-0.2408image
ENSG00000142166.11,IFNAR1GBMEAGMacrophages_M17.6254e-040.2603image
chr21:33357576-33358815:+HNSCEERPlasma_cells5.5954e-05-0.1892image
ENSG00000142166.11,IFNAR1HNSCEAGPlasma_cells9.5335e-05-0.1823image
ENSG00000142166.11,IFNAR1KICHEAGT_cells_CD4_memory_activated1.4438e-020.3021image
chr21:33357576-33358815:+KIRCEERT_cells_CD4_memory_activated1.0217e-030.1687image
ENSG00000142166.11,IFNAR1KIRCEAGT_cells_CD4_memory_activated2.3456e-040.1886image
chr21:33357576-33358815:+KIRPEERT_cells_regulatory_(Tregs)1.9813e-020.1415image
ENSG00000142166.11,IFNAR1KIRPEAGT_cells_regulatory_(Tregs)1.1582e-020.1532image
chr21:33357576-33358815:+LAMLEERT_cells_follicular_helper5.0489e-030.3387image
ENSG00000142166.11,IFNAR1LAMLEAGT_cells_follicular_helper1.0834e-030.3799image
chr21:33357576-33358815:+LGGEERMacrophages_M25.5688e-050.1748image
ENSG00000142166.11,IFNAR1LGGEAGMacrophages_M29.7749e-060.1915image
chr21:33357576-33358815:+LIHCEERMacrophages_M12.2958e-040.1941image
ENSG00000142166.11,IFNAR1LIHCEAGMacrophages_M16.4236e-040.1798image
chr21:33357576-33358815:+LUADEERT_cells_CD4_memory_activated1.0491e-070.2355image
ENSG00000142166.11,IFNAR1LUADEAGT_cells_CD4_memory_resting3.0129e-07-0.2267image
chr21:33357576-33358815:+LUSCEERT_cells_CD83.4086e-040.1647image
ENSG00000142166.11,IFNAR1LUSCEAGT_cells_CD87.0084e-040.1556image
chr21:33357576-33358815:+OVEERT_cells_CD84.4479e-030.1669image
ENSG00000142166.11,IFNAR1OVEAGT_cells_CD88.1408e-030.1554image
chr21:33357576-33358815:+PAADEERMacrophages_M02.1374e-020.1749image
ENSG00000142166.11,IFNAR1PAADEAGMacrophages_M03.4306e-020.1610image
chr21:33357576-33358815:+PCPGEERT_cells_CD4_memory_resting1.5260e-03-0.2406image
ENSG00000142166.11,IFNAR1PCPGEAGT_cells_CD4_memory_resting2.0556e-03-0.2341image
chr21:33357576-33358815:+PRADEERT_cells_gamma_delta1.0970e-020.1154image
ENSG00000142166.11,IFNAR1PRADEAGT_cells_gamma_delta1.2139e-020.1137image
ENSG00000142166.11,IFNAR1READEAGDendritic_cells_activated1.1518e-020.2667image
chr21:33357576-33358815:+SARCEERMast_cells_resting5.6616e-04-0.2187image
ENSG00000142166.11,IFNAR1SARCEAGMast_cells_resting5.1599e-04-0.2202image
chr21:33357576-33358815:+SKCMEERT_cells_CD87.2395e-100.2886image
ENSG00000142166.11,IFNAR1SKCMEAGT_cells_CD81.2244e-090.2845image
chr21:33357576-33358815:+STADEERB_cells_memory3.0650e-03-0.1585image
ENSG00000142166.11,IFNAR1STADEAGB_cells_memory1.5046e-02-0.1295image
ENSG00000142166.11,IFNAR1TGCTEAGT_cells_CD4_memory_activated2.9570e-040.3463image
ENSG00000142166.11,IFNAR1THCAEAGB_cells_naive8.7339e-040.1497image
ENSG00000142166.11,IFNAR1THYMEAGT_cells_CD4_naive3.2070e-04-0.3596image
chr21:33357576-33358815:+UCECEERT_cells_CD4_memory_resting1.9471e-04-0.3016image
ENSG00000142166.11,IFNAR1UCECEAGT_cells_CD4_memory_resting2.4182e-04-0.2964image
chr21:33357576-33358815:+UCSEERT_cells_CD4_memory_activated2.7078e-020.3191image
ENSG00000142166.11,IFNAR1UCSEAGT_cells_CD4_memory_activated2.2558e-020.3221image
ENSG00000142166.11,IFNAR1UVMEAGT_cells_regulatory_(Tregs)1.0573e-020.3225image


Top

6. Enriched editing regions and immune gene sets for IFNAR1


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr21:33357576-33358815:+HNSCEER3.1857e-02image5.8075e-030.1301image
ENSG00000142166.11,IFNAR1HNSCEAG4.2912e-02image6.0766e-030.1287image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000142166.11,IFNAR1LUADEAG1.4357e-150.34674.5514e-140.32881.6578e-130.32188.3770e-100.2700image
chr21:33357576-33358815:+LUADEER7.0922e-180.37292.8056e-160.35557.8062e-150.33874.9068e-110.2890image
ENSG00000142166.11,IFNAR1PAADEAG1.5603e-030.23872.4019e-030.22941.5780e-020.18336.2555e-030.2071image
chr21:33357576-33358815:+PAADEER1.6929e-030.23702.8032e-030.22591.7818e-020.18004.3092e-030.2160image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000142166.11,IFNAR1ACCGSVA_HALLMARK_PEROXISOMEEAG5.3087e-03-0.3345image
ENSG00000142166.11,IFNAR1BLCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG8.9003e-050.2056image
chr21:33357576-33358815:+BLCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.3379e-040.2011image
chr21:33357576-33358815:+BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER9.5933e-170.2516image
ENSG00000142166.11,IFNAR1BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.1304e-140.2343image
chr21:33357576-33358815:+CESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER6.1727e-050.2362image
ENSG00000142166.11,IFNAR1CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.6784e-040.2223image
ENSG00000142166.11,IFNAR1CHOLGSVA_HALLMARK_MYC_TARGETS_V2EAG1.6933e-020.4129image
ENSG00000142166.11,IFNAR1COADGSVA_HALLMARK_ANGIOGENESISEAG3.5117e-030.1797image
chr21:33357576-33358815:+COADGSVA_HALLMARK_ANGIOGENESISEER2.0363e-040.2284image
ENSG00000142166.11,IFNAR1DLBCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG8.9782e-030.4031image
chr21:33357576-33358815:+ESCAGSVA_HALLMARK_MTORC1_SIGNALINGEER1.8128e-020.1878image
ENSG00000142166.11,IFNAR1ESCAGSVA_HALLMARK_MTORC1_SIGNALINGEAG3.8842e-030.2278image
chr21:33355740-33355909:+GBMGSVA_HALLMARK_HEME_METABOLISMEER1.4788e-020.3612image
ENSG00000142166.11,IFNAR1GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG7.3684e-080.4052image
chr21:33357576-33358815:+GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.4267e-080.4249image
chr21:33357576-33358815:+HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.0394e-090.2832image
ENSG00000142166.11,IFNAR1HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.0163e-090.2720image
ENSG00000142166.11,IFNAR1KICHGSVA_HALLMARK_APICAL_SURFACEEAG3.2884e-03-0.3593image
chr21:33357576-33358815:+KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.6602e-070.2505image
ENSG00000142166.11,IFNAR1KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG9.1256e-050.2004image
ENSG00000142166.11,IFNAR1KIRPGSVA_HALLMARK_UV_RESPONSE_DNEAG2.7220e-04-0.2195image
chr21:33357576-33358815:+KIRPGSVA_HALLMARK_UV_RESPONSE_DNEER2.5689e-03-0.1825image
ENSG00000142166.11,IFNAR1LAMLGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.8221e-03-0.3391image
chr21:33357576-33358815:+LAMLGSVA_HALLMARK_SPERMATOGENESISEER1.5806e-020.2938image
chr21:33357576-33358815:+LGGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.2000e-290.4602image
ENSG00000142166.11,IFNAR1LGGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.5442e-250.4337image
ENSG00000142166.11,IFNAR1LIHCGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.4561e-110.3474image
chr21:33357576-33358815:+LIHCGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.6889e-130.3775image
chr21:33357576-33358815:+LUADGSVA_HALLMARK_E2F_TARGETSEER1.0610e-170.3710image
ENSG00000142166.11,IFNAR1LUADGSVA_HALLMARK_E2F_TARGETSEAG3.3570e-140.3304image
chr21:33357576-33358815:+LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.3840e-060.2126image
ENSG00000142166.11,IFNAR1LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG6.5868e-060.2060image
ENSG00000142166.11,IFNAR1MESOGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.5898e-020.2350image
chr21:33357576-33358815:+OVGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER9.3315e-060.2574image
ENSG00000142166.11,IFNAR1OVGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.3995e-050.2525image
ENSG00000142166.11,IFNAR1PAADGSVA_HALLMARK_GLYCOLYSISEAG3.1473e-030.2233image
chr21:33357576-33358815:+PAADGSVA_HALLMARK_GLYCOLYSISEER2.1339e-030.2320image
chr21:33357576-33358815:+PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.2996e-040.2782image
ENSG00000142166.11,IFNAR1PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG8.2409e-040.2534image
chr21:33357576-33358815:+PRADGSVA_HALLMARK_ANDROGEN_RESPONSEEER9.3288e-05-0.1765image
ENSG00000142166.11,IFNAR1PRADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG5.7864e-05-0.1814image
chr21:33357576-33358815:+SARCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER1.3677e-040.2413image
ENSG00000142166.11,IFNAR1SARCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG6.6204e-040.2161image
chr21:33357576-33358815:+SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.1669e-080.2563image
ENSG00000142166.11,IFNAR1SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.6239e-070.2465image
ENSG00000142166.11,IFNAR1STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.2157e-050.2165image
chr21:33357576-33358815:+STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.8170e-070.2756image
ENSG00000142166.11,IFNAR1TGCTGSVA_HALLMARK_E2F_TARGETSEAG7.3012e-030.2604image
ENSG00000142166.11,IFNAR1THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG3.6458e-070.2271image
ENSG00000142166.11,IFNAR1THYMGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.6806e-07-0.5037image
chr21:33357576-33358815:+UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.2814e-050.3297image
ENSG00000142166.11,IFNAR1UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.2833e-040.3086image
chr21:33357576-33358815:+UCSGSVA_HALLMARK_MYC_TARGETS_V1EER8.7393e-030.3745image
ENSG00000142166.11,IFNAR1UCSGSVA_HALLMARK_MYC_TARGETS_V2EAG3.0919e-020.3056image
ENSG00000142166.11,IFNAR1UVMGSVA_HALLMARK_DNA_REPAIREAG1.8814e-020.2976image


Top

7. Enriched editing regions and drugs for IFNAR1


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000142166.11,IFNAR1ACCAG.014699EAG5.6540e-04-0.4074image
chr21:33357576-33358815:+BLCACisplatinEER1.5647e-06-0.2513image
ENSG00000142166.11,IFNAR1BLCACisplatinEAG9.4279e-07-0.2557image
chr21:33357576-33358815:+BRCAJNK.Inhibitor.VIIIEER2.5423e-04-0.1123image
ENSG00000142166.11,IFNAR1BRCACHIR.99021EAG2.7136e-030.0921image
ENSG00000142166.11,IFNAR1CESCCGP.60474EAG1.3298e-04-0.2256image
chr21:33357576-33358815:+CESCCGP.60474EER5.7480e-05-0.2372image
chr21:33357576-33358815:+COADCGP.082996EER2.0929e-03-0.1900image
ENSG00000142166.11,IFNAR1COADImatinibEAG6.9068e-04-0.2083image
ENSG00000142166.11,IFNAR1DLBCJNJ.26854165EAG3.5311e-03-0.4453image
chr21:33357576-33358815:+ESCAABT.263EER3.3702e-020.1696image
ENSG00000142166.11,IFNAR1ESCAIPA.3EAG3.6756e-030.2298image
chr21:33355740-33355909:+GBMAZD6482EER1.6577e-04-0.5326image
chr21:33357576-33358815:+GBMBMS.754807EER1.8970e-080.4215image
ENSG00000142166.11,IFNAR1GBMCyclopamineEAG7.7704e-07-0.3746image
chr21:33357576-33358815:+HNSCBMS.708163EER1.4381e-07-0.2454image
ENSG00000142166.11,IFNAR1HNSCBMS.708163EAG3.6262e-07-0.2363image
ENSG00000142166.11,IFNAR1KICHBIRB.0796EAG1.6258e-04-0.4511image
ENSG00000142166.11,IFNAR1KIRCCCT007093EAG5.4325e-060.2321image
chr21:33357576-33358815:+KIRCGemcitabineEER2.4705e-05-0.2156image
chr21:33357576-33358815:+KIRPAZD6482EER1.2628e-040.2308image
ENSG00000142166.11,IFNAR1KIRPAZD6482EAG2.0443e-050.2556image
ENSG00000142166.11,IFNAR1LAMLJNK.9LEAG8.2144e-040.3882image
chr21:33357576-33358815:+LAMLBleomycinEER2.0626e-020.2823image
ENSG00000142166.11,IFNAR1LGGBexaroteneEAG6.7710e-26-0.4366image
chr21:33357576-33358815:+LGGBexaroteneEER1.0701e-25-0.4350image
ENSG00000142166.11,IFNAR1LIHCAZD6482EAG1.1203e-05-0.2302image
chr21:33357576-33358815:+LIHCBMS.708163EER1.0520e-05-0.2312image
chr21:33357576-33358815:+LUADGW843682XEER2.6875e-12-0.3066image
ENSG00000142166.11,IFNAR1LUADJW.7.52.1EAG3.7526e-11-0.2901image
ENSG00000142166.11,IFNAR1LUSCGemcitabineEAG1.4956e-03-0.1459image
chr21:33357576-33358815:+LUSCGemcitabineEER5.5195e-04-0.1589image
ENSG00000142166.11,IFNAR1MESOCGP.082996EAG1.4118e-02-0.2734image
chr21:33357576-33358815:+OVAZD.2281EER8.2748e-07-0.2856image
ENSG00000142166.11,IFNAR1OVAZD.2281EAG2.0703e-06-0.2755image
ENSG00000142166.11,IFNAR1PAADFTI.277EAG1.8706e-03-0.2348image
chr21:33357576-33358815:+PAADFTI.277EER2.2617e-03-0.2307image
chr21:33357576-33358815:+PCPGAMG.706EER7.5818e-030.2035image
ENSG00000142166.11,IFNAR1PCPGAMG.706EAG1.2940e-020.1897image
ENSG00000142166.11,IFNAR1PRADEpothilone.BEAG1.4784e-070.2356image
chr21:33357576-33358815:+PRADEpothilone.BEER2.2216e-070.2326image
ENSG00000142166.11,IFNAR1READGefitinibEAG2.4581e-020.2382image
ENSG00000142166.11,IFNAR1SARCBMS.708163EAG2.9726e-030.1890image
chr21:33357576-33358815:+SARCBMS.708163EER1.9556e-030.1969image
chr21:33357576-33358815:+SKCMCI.1040EER7.5757e-04-0.1602image
ENSG00000142166.11,IFNAR1SKCMBortezomibEAG8.5629e-04-0.1584image
ENSG00000142166.11,IFNAR1STADBMS.509744EAG2.5902e-03-0.1601image
chr21:33357576-33358815:+STADBMS.509744EER1.2720e-03-0.1723image
ENSG00000142166.11,IFNAR1TGCTBI.D1870EAG1.8030e-03-0.3011image
ENSG00000142166.11,IFNAR1THCACI.1040EAG2.8933e-08-0.2471image
ENSG00000142166.11,IFNAR1THYMABT.263EAG5.2760e-070.4857image
chr21:33357576-33358815:+UCECBIRB.0796EER1.5572e-03-0.2578image
ENSG00000142166.11,IFNAR1UCECBIRB.0796EAG2.5415e-03-0.2455image
chr21:33357576-33358815:+UCSLFM.A13EER2.3561e-030.4288image
ENSG00000142166.11,IFNAR1UCSLFM.A13EAG7.2659e-030.3752image
ENSG00000142166.11,IFNAR1UVMAZD7762EAG1.3531e-02-0.3121image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType
chr21:33355740-33355909:+ENST00000270139.6P17181DB00008Peginterferon alfa-2aBiotechDrug
chr21:33355740-33355909:+ENST00000270139.6P17181DB00011Interferon alfa-n1BiotechDrug
chr21:33355740-33355909:+ENST00000270139.6P17181DB00018Interferon alfa-n3BiotechDrug
chr21:33355740-33355909:+ENST00000270139.6P17181DB00022Peginterferon alfa-2bBiotechDrug
chr21:33355740-33355909:+ENST00000270139.6P17181DB00034Interferon alfa-2aBiotechDrug
chr21:33355740-33355909:+ENST00000270139.6P17181DB00060Interferon beta-1aBiotechDrug
chr21:33355740-33355909:+ENST00000270139.6P17181DB00068Interferon beta-1bBiotechDrug
chr21:33355740-33355909:+ENST00000270139.6P17181DB00069Interferon alfacon-1BiotechDrug
chr21:33355740-33355909:+ENST00000270139.6P17181DB00105Interferon alfa-2bBiotechDrug
chr21:33355740-33355909:+ENST00000270139.6P17181DB09122Peginterferon beta-1aBiotechDrug
chr21:33355740-33355909:+ENST00000270139.6P17181DB11976AnifrolumabBiotechDrug
chr21:33355740-33355909:+ENST00000270139.6P17181DB14999Human interferon betaBiotechDrug
chr21:33355740-33355909:+ENST00000270139.6P17181DB15119Ropeginterferon alfa-2bBiotechDrug
chr21:33357576-33358815:+ENST00000270139.6P17181DB00008Peginterferon alfa-2aBiotechDrug
chr21:33357576-33358815:+ENST00000270139.6P17181DB00011Interferon alfa-n1BiotechDrug
chr21:33357576-33358815:+ENST00000270139.6P17181DB00018Interferon alfa-n3BiotechDrug
chr21:33357576-33358815:+ENST00000270139.6P17181DB00022Peginterferon alfa-2bBiotechDrug
chr21:33357576-33358815:+ENST00000270139.6P17181DB00034Interferon alfa-2aBiotechDrug
chr21:33357576-33358815:+ENST00000270139.6P17181DB00060Interferon beta-1aBiotechDrug
chr21:33357576-33358815:+ENST00000270139.6P17181DB00068Interferon beta-1bBiotechDrug
chr21:33357576-33358815:+ENST00000270139.6P17181DB00069Interferon alfacon-1BiotechDrug
chr21:33357576-33358815:+ENST00000270139.6P17181DB00105Interferon alfa-2bBiotechDrug
chr21:33357576-33358815:+ENST00000270139.6P17181DB09122Peginterferon beta-1aBiotechDrug
chr21:33357576-33358815:+ENST00000270139.6P17181DB11976AnifrolumabBiotechDrug
chr21:33357576-33358815:+ENST00000270139.6P17181DB14999Human interferon betaBiotechDrug
chr21:33357576-33358815:+ENST00000270139.6P17181DB15119Ropeginterferon alfa-2bBiotechDrug